Raman Pharma is a UK based MHRA and VMD Licensed Wholesaler supplying to the Human and Veterinary Market. We are a family run company ambitiously changing the face of the Pharmaceutical and Veterinary Market alike in order to serve the needs of our customers and their patients.
Our Philosophy and business are structured around the requirements of our customers and we are committed to giving them our upmost attention and care. We believe in delivering quality and value to our customers wherever they may be.
The Herbal Horse and Pet is a South African manufacturer of a very innovative range of supplements for horses, dogs and cats. Their philosophy of using a large number of different ingredients in small amounts mimics nature in that the healing effect of the ingredients is maximised while undesirable side-effects are minimised. These unique formulations, in conjunction with 21st century scientific research and techniques are what they call “cutting edge nature”.
They are manufactured in a GMP Compliant Factory and has a large following from riders and pet owners across the world. Please follow the link to the website – www.theherbalhorse.co.uk to see all the amazing blogs and the ability to purchase these products online. The Equine and Pet Range were introduced to the UK Market in September 2014 by Raman Pharma to give the UK a taste of the future in equine and companion animal nutritional supplements.
In today’s Primary Care Bulletin email, NHS England and NHS Improvement (NHSE&I) confirmed that there is currently no intention to issue a national or regional direction for community pharmacies to open on Bank Holidays over the coming Christmas and New Year period, as happened at Easter this year. NHSE&I indicated it was extremely grateful for...
Flu vaccinations for 50-64 year olds* can commence today (Tuesday 1st December 2020) under the terms of the flu vaccination Advanced service. This follows the Government’s announcement, earlier this year, that the 2020 flu vaccination programme would be extended with the addition of this new cohort, so it would become the largest programme ever undertaken...
Update: (30/11/2020) Resupply dates revised below Department of Health and Social Care (DHSC) has issued a medicine supply notification for Oral Contraceptive tablets (various brands) The following oral contraceptive preparations are currently out of stock Product affected Ingredients Anticipated Resupply Date Management Advice Brevinor Ethinylestradiol/norethisterone 35microgram/500 microgram tablets w/c 11 January 2021 No exact equivalent...
The Community Pharmacy IT Group (CP ITG) has, today, published its Pharmacy IT quarterly round-up (Winter 2020 edition). This follows the group’s quarterly meeting on 18th November 2020, where a range of topics were discussed, including: the deployment of Real Time Exemption Checking and contractor acceptance of the user agreement; the new NHS Service Finder...
Update 30/11/2020 Anticipated resupply date now mid December 2020 Department of Health and Social Care (DHSC) has issued a medicine supply notification for Ferrous Fumarate 322mg/Folic Acid 350mcg (Pregaday) tablets (Recipharm) Pregaday tablets will be out of stock until October 2020. UKMI have provided clinical advice on switching to alternative iron and folic acid containing...
Update (30/11/2020): Normacol granules back in stock, Normacol Plus granules now expected w/c 21st December 2020 Department of Health and Social Care (DHSC) has issued a medicine supply notification for Sterculia (Normacol) 62% w/w granules, Sterculia & Frangula Bark (Normacol Plus) 62%/8% w/w granules Normacol and Normacol Plus granules are out of stock until 13th...
Update (30/11/2020) – Resupply date now expected to be w/e 4th December 2020 Department of Health and Social Care (DHSC) has issued a medicine supply notification for Nalcrom (sodium cromoglicate) 100mg capsules Nalcrom 100mg capsules will be out of stock until late November 2020 Unlicensed imports of sodium cromoglicate 100mg capsules have been sourced, the...
Update (30/11/2020) – Due to changes in the availability of Bisacodyl suppositories – an updated overview can be found below: Product Supplier Current Stock Position Anticipated resupply date Bisacodyl 5mg suppositories Sanofi Out of stock Early January 2021 Bisacodyl 10mg suppositories Sanofi Out of stock Limited supplies expected January 2021, full resupplies expected March 2021...
Department of Health and Social Care (DHSC) has today (30/11/2020) set the FINAL price concessions for November 2020. The new additions to the November 2020 price concession list are below: Drug Pack Size Price Concession Alendronic acid 10mg tablets 28 £6.60 Duloxetine 40mg gastro-resistant capsules 56 £13.96 Entacapone 200mg tablets 30 £9.95 Esomeprazole 40mg gastro-resistant capsules...
NHS England and NHS Improvement (NHSE&I) have published several documents for community pharmacy contractors relating to the COVID-19 vaccination programme. The documents will be of interest to contractors that are considering whether they may be able to participate in the programme, by operating a vaccination site, where this is agreed by NHSE&I. Letter to pharmacy...
Department of Health and MHRA register of licensed manufacturing sites - manufacturer specials (human) (MS) and manufacturer specials authorisation (veterinary) (MANSA) only.
Department of Health and Social Care and MHRA register of licensed wholesale distribution sites (human and veterinary).
List of sites granted a manufacturer or wholesale dealer licence
Current listing of UK brokers authorised to broker human medicines, including company name, registration and address.
List of companies in the UK who have their licence to manufacture or wholesale medicines terminated and cancelled.
List of manufacturers and their medical devices which have been granted an exemption by the MHRA. The list also includes manufacturers whose exemption expired or was cancelled. This information will be listed for 2 months after expiry or cancellation.
How the ‘Written Confirmation’ process for active substances manufactured in Great Britain (England, Wales and Scotland) will be handled from 1 January 2021.
This guidance covers ‘grandfathering’ and managing the lifecycle changes of medicinal products.
List of field safety notices (FSNs) from medical device manufacturers from 23 to 27 November 2020.
This guidance summarises our approach to pharmacovigilance from 1 January 2021.
The Medicines and Healthcare products Regulatory Agency (MHRA) assesses its regulatory impact on businesses.
Medicines that were granted a positive opinion under the early access to medicines scheme (EAMS) which has now expired.
The safety of the public will always come first.
The following guidance has been jointly developed by the Heath Research Authority (HRA) and MHRA, in consultation with the Information Commissioners Office (ICO), on behalf of the UK.
Sanofi is recalling specific batches of Largactil 50mg/2ml Solution for Injection as a precautionary measure due to out of specification results obtained for the impurity chlorpromazine sulphoxide
How to notify MHRA of your intention to carry out a clinical investigation for CE marking.
Kent Pharmaceuticals Ltd has informed us that several batches of finished product were contaminated with theophylline due to a cross-contamination issue identified with an excipient that was used in the manufacture of the finished product.
Guidance on how to get an e-cigarette on the market in the UK, including the notification scheme and reporting problems with e-cigarettes.
Kyowa Kirin Limited is recalling specific batches as a precautionary measure, due to the reports of double tablets in a single blister pocket.
From 1 January 2021, new rules mean notifications from Great Britain and Northern Ireland will need to be sent to different routes
Details of seizure notice served following a parcel addressed to premises in County Tyrone stopped at a Belfast Depot.
Guidance for the pharmaceutical industry on location and other authorised personnel requirements post transition period.
Guidance for the pharmaceutical industry on the batch release scheme for an immunological veterinary medicinal product to be placed on to the UK market from 1 January 2021.
Guidance for the pharmaceutical industry on how to apply for and manage an authorisation to place a veterinary medicine on the UK market post transition period. This guidance will be updated with more information as it becomes available.
This report (UK VARSS) provides the details of UK veterinary antibiotic resistance and sales surveillance.
How to legally run a business that deals with the wholesale of animal medicines (veterinary medicinal products) and the WDA Register.
Joint VMD and Veterinary Products Committee (VPC) open information day on Wednesday 18 November.
VMD’s Regulatory Science Strategy, a stakeholder consultation with feedback requested by 31 January 2021.
New UK VARSS annual report shows UK sales of antibiotics in food-producing animals have halved since 2014.
Residues of veterinary medicines in food 2019 surveillance results.
Details of seizure notice served to Border Force, Heathrow Airport following a routine search.
Details of seizure notice served to Border Force, East Midlands Airport.
Details of seizure notice served to Border Force, Heathrow Airport following a routine search.
Marketing Authorisation Holders (MAHs) have informed the VMD of supply problems with the following lactating cow intramammary antibiotics.
Reporting against VMD published standards up to 31 March 2021
Guidance for the veterinary pharmaceutical industry on how to convert a Centrally Authorised Product (CAP) to a national GB Marketing Authorisation.
Guidance for the pharmaceutical industry on importing and exporting veterinary medicines post transition period.
Marketing Authorisations Information Service (MAVIS) Hub edition 116
Advice for vets and beekeepers to help them legally import bee medicines when a UK authorised product is not suitable.
As a vet or pharmacist, you must follow legal requirements when working with controlled drugs in veterinary medicine.
Grünenthal will pay $320m upfront for the rights
Follows on from success of the inaugural Patient Partnership Index Conference
Research conducted at Oxford University used new scanning method
Companies will aim to advance drug discovery for synucleinopathies
Commonly used anti-inflammatory drug added to list of potential treatments
Survey included input from scientists at The Institute of Cancer Research, London
First biologic to be approved for children aged six to 11 years with condition
New agreement takes supply up to seven million doses in total
The combination is the first available to treat the underlying cause of CF in this patient group.
Tepotinib could be the first treatment on the market for NSCLC in adults harbouring METex14 skipping alterations
Trial results and cost-effectiveness are too uncertain for NHS use, the Institute said
It is hoped that the test will help detect cancer at a much earlier stage
Sanofi's Sarclisa gets the final green light for use by the NHS with funding from the CDF
Delivery of vaccine doses to EU could begin by early 2021
Tremfya is a first-in-class treatment for the disease, shown to improve disease measures and quality of life
Unit 2 Fleet Business Park, Sandy Lane, Church Crookham, Fleet, Hampshire, GU52 8BF
Pharmaceutical and Veterinary Licensed Distributor. WDA (H) 43703 & WDA (V) 43703.
- +44 (0)1252 260 460.
- +44 (0)1276 469 290
Monday to Friday - 09:30 – 18:30
Saturday & Sunday - Closed, Online Ordering Available